Key result
Gemfibrozil improves lipid profiles and fibrinolytic activity versus placebo, linking higher HDL to increased t-PA.
Why the study?
The effects of gemfibrozil on fibrinolysis and plasma lipoprotein levels in patients with primary hypertriglyceridemia were investigated to understand its role beyond lipid regulation.
Does gemfibrozil 600 mg b.i.d. improve lipid profiles and fibrinolytic parameters in patients with primary hypertriglyceridemia?
Population
20 patients with primary hypertriglyceridemia (Fredrickson's type IV), age 52 +/- 3 years
Comparison
Gemfibrozil 600 mg b.i.d. vs placebo
Design
Randomized double-blind study
Follow-up
12 weeks
Authors
Loading...
Supports gemfibrozil for dual lipid-fibrinolytic benefits in hypertriglyceridemia; confirms lipid effects while extending evidence to hemostatic parameters.
RCT (n=20)
Double-blind
Randomized
Does gemfibrozil 600 mg b.i.d. improve lipid profiles and fibrinolytic parameters in patients with primary hypertriglyceridemia?
Gemfibrozil improves both lipid profiles and fibrinolytic system parameters in patients with primary hypertriglyceridemia.
Avellone et al. (1995) conducted an RCT in Primary hypertriglyceridemia (Fredrickson's type IV) (n=20). Gemfibrozil vs. Placebo was evaluated on Lipid levels and fibrinolytic parameters. Gemfibrozil significantly improved lipid profiles and fibrinolytic activity compared to placebo, with a positive correlation between HDL cholesterol and t-PA:Ag post-venous occlusion (r=0.56, P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: